Press & Media Coverage
Catch up on our latest press coverage
Positive Results from IBI10103 Phase I Study with MagSense® HER2 Imaging Agent
https://youtu.be/LI18OcgM9XM Imagion Announces Positive Results from IBI10103 Phase I Study Demonstrating Safety and Clinical Feasibility of Molecular MRI with MagSense® HER2 Imaging Agent Imagion Biosystems
[VIDEO] EGM Recording – 13 November 2023
https://youtu.be/hThLkmpJPW0 EGM 13 November 2023 Video transcript: Welcome and thanks for joining us. Both those joining virtually and those in person. As the time is
Quarterly Activity Report – Quarter ending 30 September 2023
Highlights: Announced preliminary performance of MagSense® HER2 Imaging Agent in phase 1 study after study closure (post quarter end) Entered a strategic partnership with Prestige
[VIDEO] ShareCafe Hidden Gems Webinar Oct 2023
Imagion’s CEO, Isaac Bright, presents our latest investor opportunities at ShareCafe’s Hidden Gems Webinar on 20 October 2023. https://youtu.be/XCfQ64VeVCg Video Transcript: First up, we have
[VIDEO] 2023 EGM Resolution Overview
Earlier this month, Imagion announced our upcoming EGM meeting to be held on 13th November, along with several resolutions to be voted on by shareholders. Here, Imagion
Preliminary Performance of Phase I Study: MagSense® HER2 Imaging Agent
Highlights • Encouraging top-line performance of world’s first molecular MRI test • Pathology results from lymph node tissue shows concordance with MRI imaging MELBOURNE —
Watch our latest media coverage
Transforming medical imaging for early disease detection
We’re on a mission to make cancer more detectable.